Compliance Considerations For Pharma Co. Testing Programs
By Eve Brunts and Alison Fethke (June 7, 2021, 5:52 PM EDT) -- With the rise in precision medicine and increased awareness of rare and ultra-rare conditions, health care providers and patients are seeking more information to guide diagnosis and treatment decisions. Information about a patient's genetic markers or antibodies, obtained through diagnostic testing, can improve the accuracy of diagnoses and inform decisions about the potential effectiveness of drug treatment for particular patients.
Pharmaceutical companies are increasingly considering how they can appropriately assist patients in accessing such diagnostic tests. Such assistance may include offering or supporting free testing programs.
The programs may, however, raise potential compliance considerations, including fraud and abuse, U.S. Food and Drug...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!